Breast Cancer Trial, Recruiting NCT04278469 Sponsor: Gencurix, Inc. Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT04278469
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women between the ages of 19 and 80 at the time of screening
  • People whose breast cancer has been confirmed by a laboratory test (biopsy) to be an invasive type
  • People whose cancer is fuelled by hormones — specifically, testing positive for estrogen receptors (ER+) and/or progesterone receptors (PR+)
  • People whose cancer tests negative for a protein called HER2 (HER2-)
  • People whose underarm (axillary) lymph nodes show either no cancer spread (pN0) or only a small amount of spread (pN1) (confirm with trial site)
  • People whose tumour measures 0.5 cm or larger
  • People whose cancer is assessed as "clinically high risk" using a specific risk calculation tool called modified Adjuvant! Online (confirm with trial site)
  • People who agree to have genetic testing done
  • People whose major organs (such as liver and kidneys) are functioning adequately
  • People whose cancer is assessed as "genomically low risk" using a specific test called GenesWell BCT (confirm with trial site)
  • People with a new, first-time primary breast cancer (not a recurrence)
  • People who have had surgery with the aim of fully removing the cancer
  • People who have given their own written consent to participate in the trial

Who may not be able to join:

  • People whose cancer tests negative for both estrogen and progesterone receptors (ER- and PR-)
  • People whose cancer tests positive for the HER2 protein (HER2+)
  • People whose cancer has spread more extensively to the underarm lymph nodes (pN2 or pN3)
  • People who received chemotherapy before their surgery
  • People who received radiotherapy before their surgery
  • People whose tumour is smaller than 0.5 cm
  • People whose cancer is assessed as "clinically low risk" using the risk calculation tool
  • People for whom a preserved tumour tissue sample (FFPE) is not available for testing
  • People who have chronic liver disease, a history of stroke or other cerebrovascular disease, a long-term mental health condition, or who are pregnant, breastfeeding, or of childbearing potential
  • People whom the trial investigators consider unsuitable for participation for other medical reasons
  • People who have had breast cancer before or have previously been treated for breast cancer
  • People who have not yet had surgery

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 010-7346-2841

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Gencurix, Inc.
Registry
ClinicalTrials.gov
Start date
11 January 2019
Est. completion
1 January 2029

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

10-year distant metastasis free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov